

VEGF-induced intracellular Ca^{2+} oscillations are weaker and do not stimulate proliferation in tumor-derived endothelial colony forming cells

Germano Guerra¹, Francesco Lodola², Umberto Laforenza³, Fabio Cattaneo⁴, Valentina Poletto⁵, Estella Zuccolo², Marco Biggiogera⁶, Vittorio Rosti⁵, Domenico Tafuri⁷, Francesco Moccia²

¹ Department of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Via F. De Santis, 86100 Campobasso, Italy.

² Laboratory of General Physiology, Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy;

³ Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy;

⁴ Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy;

⁵ Center for the Study of Myelofibrosis, Research Laboratory of Biotechnology, Foundation IRCCS Policlinico San Matteo, 27100 Pavia, Italy;

⁶ Laboratory of Cell Biology and Neurobiology, Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy;

⁷ Department of Sport Sciences and Wellness, University of Naples "Parthenope", Naples, Italy.

Endothelial colony forming cells (ECFCs) represent a population of truly endothelial precursors that may be mobilized from their vascular stem cell niches to promote the angiogenic switch in a growing number of solid malignancies, including breast cancer (BC). While normal ECFCs require VEGF to proliferate, tumor-associated ECFCs are seemingly insensitive to this growth factor. This phenomenon could contribute to the relative failure of anti-VEGF therapies in cancer patients. Recent work showed that the intracellular Ca^{2+} toolkit, which is a crucial determinant of ECFC fate and controls the pro-angiogenic program triggered by VEGF, is remodelled in tumor-associated ECFCs. Herein, we adopted an array of techniques, including Ca^{2+} imaging, electron microscopy, flow cytometry, real-time polymerase chain reaction, western blot analysis and functional assay to investigate whether and how VEGF uses Ca^{2+} signalling to control proliferation in BC-derived ECFCs (BC-ECFCs). Our results finally demonstrate for the first time that BC-ECFCs are insensitive to VEGF, which might explain at cellular and molecular level the failure of anti-VEGF therapies in BC patients, and hint at SOCE as a novel molecular target for this disease.

Keywords

VEGF, breast cancer, endothelial colony forming cells, intracellular Ca^{2+} oscillations, proliferation